FDA
No application listedNo application naming 5-amino-1MQ as an active ingredient is listed in Drugs@FDA. Checked 2026-10-05; the control lookup (semaglutide) returned 6 applications.
Drugs@FDA via openFDA5-Amino-1MQ: chemistry, literature and regulatory status
Research-use information. This page summarises published literature and regulator records. It is not guidance for use, not medical advice, and not a statement that any material is suitable for use in people or animals.
What is 5-Amino-1MQ?
5-Amino-1MQ is 5-amino-1-methylquinolinium, a small molecule that is not a peptide. PubChem titles its record for CAS 42464-96-0 NNMTi, and the literature studies methylquinolinium compounds as inhibitors of nicotinamide N-methyltransferase (NNMT). It is listed as a research material for laboratory use only.
What are the chemical facts for 5-Amino-1MQ?
- Name
- 5-Amino-1MQ
- Also written
- Structure
- 5-amino-1-methylquinolinium (non-peptide)
- Molecular formula
C10H11N2+- Average molecular weight
- 159.21 g/mol
- CAS number
42464-96-0(not confirmed in PubChem)- PubChem
- CID 950107
PubChem lists CAS 42464-96-0 as the iodide salt (C10H11IN2, 286.11 g/mol) of the 5-amino-1-methylquinolinium cation (C10H11N2+, 159.21 g/mol). The salt form of a supplied material is read from its certificate.
Chemistry checked against PubChem on 2026-10-05. Where the formula can be computed from the listed sequence, it was, and the two routes agree.
How does the literature describe the mechanism of 5-Amino-1MQ?
- Structure-activity work on small-molecule NNMT inhibitors identified N-methylquinolinium scaffolds with low micromolar inhibition, the scaffold class of 5-amino-1MQ.[5]
- Membrane-permeable methylquinolinium NNMT inhibitors were tested in cell culture and in mice on a high-fat diet.[4]
- Reviews describe NNMT mechanisms and inhibitors, NNMT in metabolism and epigenetic regulation, and the obstacles to clinical translation of NNMT inhibitors.[2],[3],[1]
Receptor and pathway background: NAD+ metabolism and NNMT.
What has published research on 5-Amino-1MQ looked at?
5 studies are cited for 5-Amino-1MQ. Each is labelled by design below, and each entry says what the paper measured.
- 3 review
- 1 in vitro and animal study
- 1 chemistry and in vitro study
PubMed returns 34 records for the search terms published on the method page (2 of them with a review publication type, 0 with a clinical-trial publication type), checked 5 October 2026. ClinicalTrials.gov lists 0 registered studies whose intervention matches the name (0 interventional), checked 5 October 2026.
Studies are listed by what they measured. Papers whose titles state an amount or schedule, or describe a clinical outcome of an approved medicine, are not listed. This is a wording rule, not a quality filter; see the method page.
What is the regulatory status of 5-Amino-1MQ?
EMA
No centrally authorised medicine listedNo centrally authorised procedure in the EMA medicines database (checked 5 October 2026) names 5-amino-1MQ as an active substance. National authorisations are not in this dataset.
EMA medicines dataMHRA
No product document foundNo SmPC, PIL or PAR document in MHRA Products matches the exact name "5-amino-1MQ". Checked 2026-10-05; the control lookup (semaglutide) returned 271 documents.
MHRA ProductsWADA
Not namedThe WADA 2026 Prohibited List, in force 1 January 2026 does not name this substance. The list names substances by example, so this is not a statement that it is permitted in sport.
WADA Prohibited List 2026A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.
Data dates: regulatory records 2026-10-05; WADA list 2026-10-05.
Which studies are cited for 5-Amino-1MQ?
[1] Puleo N, Allega MF, Niemann CU, Lengyel E. Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation. Trends Pharmacol Sci. 2026;47:638-654.
Review of opportunities and obstacles for clinical translation of NNMT inhibitors.
[2] Iyamu ID, Huang R. Mechanisms and inhibitors of nicotinamide N-methyltransferase. RSC Med Chem. 2021;12:1254-1261.
Review of NNMT mechanisms and inhibitor development.
[3] Roberti A, Fernández AF, Fraga MF. Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation. Mol Metab. 2021;45:101165.
Review of NNMT at the crossroads of cellular metabolism and epigenetic regulation.
[4] Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, et al.. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152.
Tested membrane-permeable methylquinolinium NNMT inhibitors in cell culture and in diet-induced obese mice.
[5] Neelakantan H, Wang HY, Vance V, Hommel JD, McHardy SF, Watowich SJ. Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase. J Med Chem. 2017;60:5015-5028.
Structure-activity relationships of small-molecule NNMT inhibitors, identifying N-methylquinolinium scaffolds with low micromolar inhibition (the scaffold class of 5-amino-1MQ).
Data dates: citations read from PubMed 2026-10-05.
Where else in the research library is 5-Amino-1MQ covered?
Who wrote this page and how is it checked?
Peptency editorial team, last reviewed 5 October 2026. Citations are read back from PubMed, chemistry is checked against PubChem, and regulator records are read from each regulator's own database on the dates shown. The method page lists every source, search term and rule. Corrections are welcome through the contact details on the About page.